Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (648)	4/30/2002 7:57:38 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3561

I think by year-end, at NCI-AACR conference. If they can move with dosing as planed. PI is single site, and escalating TRAP dose. So, this trial type takes at least one year for several groups. Interesting that they did included specifically progressed NHL, so this may be indication for aggressive development. I am sure that they will try to learn (like with IL-1 trap) as much as possible with PI trial. I do not have any detail from protocol (if someone have, please, post), so it is hard to compare TRAP with DNA rh-anti-VEGF Ab. Miljenko